Seeking Alpha

Heat Bio doses first patient in early-stage HS-130 trial

|About: Heat Biologics, Inc. (HTBX)|By: , SA News Editor

Heat Biologics (HTBX -3.1%) has dosed the first patient in the first Phase 1 clinical trial of HS-130, in combination with HS-110, for patients with advanced solid tumors refractory to standard of care.

The trial is expected to enroll up to 30 patients. The objectives of the study are to evaluate patient safety and to determine the optimal dose for a subsequent Phase 2 trial.